Today's immunoassays (a chemical procedure for detecting infections) detect specific antibodies (blood proteins produced in response to and counteracting alien substances found in the body such as viruses and bacteria) but do not evaluate viral load (quantitative analysis), nor do they detect the antigen (the virus or bacteria itself). The HTS-MTP system utilizes technology that is simple in concept, but revolutionary in scope--allowing for the detection of the virus by "measuring" the magnetic field of micro-particles bonded to the virus in a fraction of the time and costs of existing assays. Most testing conducted in the United States today are screening assays (limited to the detection of antibodies), and are largely for detection purposes only. These tests are limited because they can only detect the presence of antibodies after a minimum infection time of two to six weeks. The Western Blot Test, the most widely used confirmatory test, again tests only for antibodies. The HTS-MTP system is designed to detect the virus (not the antibodies the human body produces to react to the virus) in a fraction of the time--72 to 96 hours. All with near 100% accuracy.

Pictured above (taken with an electronic microscope) are primary antibodies coated on the base of a testing receptacle, secondary antibodies coated on a magnetic particle, and the virus sandwiched between. This is one of the steps of our highly innovative HTS-MTP device.

According to S & P's Industry Surveys, Biotechnology, December 29, 2005 revenues for all publicly traded biotech companies (US and non-US biotech-related concerns trading on major US stock markets) are expected to reach $50 billion in 2005. One of the largest medical products segments, in-vitro diagnostics accounted for about 18% of total industry sales, based on Health Industry Manufacturers Association (HIMA) estimates.

The Company defines its markets for the first line of products as public, private laboratories and blood banks. The world market size for manufacturing is $25 billion and the US retail market is $37 billion. The area of greatest growth in the in-vitro diagnostics market will be in the area of High Throughput Screening and Viral Load Detection, two areas in which our equipment and assays will excel.

The initial markets for the Company's products will be Mexico and Thailand. Over the past 20 years management has developed key government relationships in these countries. Both countries conduct millions of HIV and Hepatitis B tests annually.

Upon completion of clinical trial Latin America and Asia, the company will initiate a 510 K Registration with the U.S. Food and Drug Administration (F.D.A.). In 2002, HIV diagnostics tests conducted in the US was 22.15 million and in 2002, Hepatitis B diagnostic tests in the US were estimated at 31 million.